urine-based cancer detection
Bringing clarity and confidence to physicians and patients through accurate, non-invasive cancer detection.
ABOUT US
Cellens is developing a highly accurate, non-invasive, urine-based diagnostic test suite to support physicians’ decisions and improve patients’ quality of life.
ADDRESSING UNMET NEEDS
IN NON-INVASIVE CANCER DETECTION
Cellens is developing a highly novel approach to detect abnormal cells in your urine
VOIDED
URINE FIXATION
STANDARD LAB
PROCESSING
HIGH RESOLUTION CELL SURFACES IMAGING
MACHINE LEARNING ANALYSIS TO DETECT MALIGNANCY
PATIENT MONITORING
High recurrence (50-80%) from non-muscle-invasive bladder cancer (NMIBC, 75% of all bladder cancer cases) requires invasive surveillance exams every 3 to 6 months. The exam, cystoscopy, consists of inserting a physical probe into the bladder through the urethra so that urologists can inspect for lesions, resulting in high lifetime costs, low patient compliance, and complications from trauma to the urethra (i.e: UTIs)
Cellens offers an accurate and noninvasive bladder cancer detection test suite to support physicians’ decisions and improve patients’ quality of life.
OUR FEEDBACKS
NEWS & BLOGS
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.
2021 | Atomic Force Microscopy Detects the Difference in Cancer Cells of Different Neoplastic Aggressiveness via Machine Learning
A novel method based on atomic force microscopy (AFM) working in Ringing mode (RM) to distinguish between two similar human colon epithelial cancer cell lines that
Cellens to receive “Bit to Bytes” award from Baker-Polito Administration and the Massachusetts Life Sciences Center
Fourteen projects receiving funding to support R&D, innovation in addressing challenges in therapeutic delivery and unlocking potential of data science to answer pressing life sciences questions
